Amanote Research
Register
Sign In
GM-CSF/Ipilimumab Combination Extends Melanoma Survival
Cancer Discovery
- United States
doi 10.1158/2159-8290.cd-nb2013-083
Full Text
Open PDF
Abstract
Available in
full text
Categories
Oncology
Date
June 6, 2013
Authors
Unknown
Publisher
American Association for Cancer Research (AACR)
Related search
Gm-CSF
Commanding CNS Invasion: GM-CSF
Immunity
Infectious Diseases
Allergy
Immunology
Anti‐GM‐CSF Therapy in Psoriasis
British Journal of Dermatology
Dermatology
Medicine
Paraneoplastic Hyperleucocytosis in a Melanoma Patient After Initiation of Ipilimumab and Nivolumab Combination Therapy
Journal for ImmunoTherapy of Cancer
Oncology
Molecular Medicine
Pharmacology
Cancer Research
Allergy
Immunology
Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Novel GM-CSF-based Vaccines: One Small Step in GM-CSF Gene Optimization, One Giant Leap for Human Vaccines
Human Vaccines and Immunotherapeutics
Medicine
Allergy
Immunology
Pharmacology
GM-CSF Administration Improves Defects in Innate Immunity and Sepsis Survival in Obese Diabetic Mice
Journal of Immunology
Allergy
Immunology
Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated With Ipilimumab
Journal for ImmunoTherapy of Cancer
Oncology
Molecular Medicine
Pharmacology
Cancer Research
Allergy
Immunology
GM-CSF Therapy in Pulmonary Alveolar Proteinosis
Thorax
Pulmonary
Respiratory Medicine